Advances in the treatments of systemic vasculitides.
Necrotizing systemic vasculitides are severe diseases in which prognosis improved since steroids and cytotoxic agents have been prescribed. The outcome is now better, and remission is obtained in more than 80% of patients. In this review paper, we will cover the indications of conventional treatments and new biotherapies and other therapies. The strategies that improve patient's outcome are discussed in the light of the prospective trials organized by international research groups.
Guillevin
Loïc
L
Service de Médecine Interne, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris René Descartes, 27 rue du Faubourg Saint-Jacques, Paris, France. loic.guillevin@cch.aphp.fr
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015267:Churg-Strauss Syndrome / Q000628:therapy; D003449:Cryoglobulinemia / Q000628:therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D006509:Hepatitis B / Q000150:complications; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D010951:Plasma Exchange; D014657:Vasculitis / Q000145:classification / Q000628:therapy*
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D016756:Immunoglobulins, Intravenous; D003520:Cyclophosphamide